100%
Skip to main content
Platform
GovTribe AI
AI-powered insights to accelerate your government contracting workflow.
MCP Server
Connect GovTribe to your AI tools.
Beacon
Find and connect with key government decision-makers.
Profiles
Federal Agencies
Federal Contract Vehicles
Federal Grant Programs
Major Defense Acquisition Programs
NAICS Categories
PSC Categories
States
Jurisdictions
NIGP Categories
UNSPSC Categories
Vendors
Enrichment By Clearbit
Reports
New Entrants
Funding Analysis
Vehicle Analysis
Groups
Capture
Pipelines
Pursuits
Alerts
Teaming
Data
Awards
Forecasts
Federal Opportunities
State & Local Opportunities
Files
Prime and Subcontractors
Activity
Search
Exports
Solutions
Use Case
Opportunity Identification
Capture Management
Competitive Intelligence
Teaming & Partner Identification
Proposal Management
Strategic Leadership
Go-to-Market Strategy
Industry
Federal Contractors
State & Local Contractors
Grant Seekers
Government Agencies
Research & Consulting
Pricing
More
About Us
Features
Get A Demo
Sign Up
Blog
User Guide
Data Model
GovTribe for Agents
Login
Contact sales
Try for free
Login
Contact sales
Try for free
All Federal Grant Awards
Project Grant W81XWH1910705
Award Date
9/1/19
Completion Date
8/31/24
Dollars Obligated
$4.5M
Overview
Activity
2
Transactions
2
Subawards
Similar Awards
Federal Agency
Defense Health Agency
Awardee
Proteogenomics Research Institute For Systems Medicine (EAZXZLPJYJZ2)
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
La Jolla, CA 92037, USA
Update #1
Update #2
ECTACS: ENDOTHELIAL CELL-TARGETED AMATOXIN CONJUGATES FOR IMPROVED THERAPY OF BREAST CANCER
Posted 8/24/19
5
1
Mod #
Description
ReasonForModification
Federal Obligation
Date
Not listed
COVID-19 ECTACS: ENDOTHELIAL CELL-TARGETED AMATOXIN CONJUGATES FOR IMPROVED THERAPY OF BREAST CANCER EXTEND THE PERIOD OF PERFORMANCE 3. PER SECTION 711 OF THE NATIONAL DEFENSE AUTHORIZATION ACT (NDAA) 2019, THE US ARMY MEDICAL RESEARCH ACQUISITION ACTIVITY (USAMRAA), US ARMY MEDICAL RESEARCH AND DEVELOPMENT COMMAND (USAMRDC) TRANSFERRED TO THE DEFENSE HEALTH AGENCY (DHA) FROM THE U.S. ARMY EFFECTIVE 01 OCTOBER 2022. THIS MODIFICATION REFLECTS CHANGES CONSISTENT WITH THE TRANSFER TO DHA AND 4. DIVISION II HAS BEEN UPDATED TO SUPERSEDE DIVISION III, PART 2, SECTION C, 2.B. ELECTRONIC PAYMENT INSTRUCTIONS
$0
7/28/23
Not listed
ECTACS: ENDOTHELIAL CELL-TARGETED AMATOXIN CONJUGATES FOR IMPROVED THERAPY OF BREAST CANCER
$4.5m
8/24/19